Core Insights - Milestone Pharmaceuticals Inc. will present at the TD Cowen 45th Annual Health Care Conference from March 3-5, 2025 [1] - A live webcast of the presentation will be available on March 4 at 9:10 AM EST, with a replay option for 90 days [2] - Milestone Pharmaceuticals focuses on developing innovative cardiovascular solutions, with its lead product being etripamil, a nasal spray for self-administration in treating symptomatic episodic attacks associated with PSVT and AFib-RVR [3]

Core Viewpoint - Milestone Pharmaceuticals has received a Notice of Allowance for a new Method of Use patent for its lead investigational product, etripamil nasal spray (proposed trade name CARDAMYST), aimed at managing paroxysmal supraventricular tachycardia (PSVT) [1][2] Group 1: Patent and Intellectual Property - The patent covers the repeat dose regimen used in the RAPID Phase 3 study for CARDAMYST, which is part of the New Drug Application (NDA) currently under FDA review [2][4] - The Notice of Allowance potentially extends intellectual property protection for CARDAMYST in the U.S. until July 2042, providing an additional 6 years of protection [2][3] Group 2: Product Development and Commercialization - Etripamil is a novel calcium channel blocker nasal spray designed for self-administration, allowing patients to manage symptomatic episodes of PSVT and AFib-RVR without immediate medical oversight [5][6] - The NDA for CARDAMYST is under FDA review with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025, and commercial preparations are advancing for an anticipated launch in mid-2025 [4][6] Group 3: Company Overview - Milestone Pharmaceuticals focuses on developing innovative cardiovascular solutions to improve the lives of patients with complex heart conditions, emphasizing unmet patient needs and self-management [6]

Core Viewpoint - Milestone Pharmaceuticals is preparing for the commercial launch of its lead investigational product, etripamil nasal spray (proposed trade name CARDAMYST™), aimed at managing paroxysmal supraventricular tachycardia (PSVT) with a launch expected in mid-2025 [2][4]. Group 1: Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative cardiovascular solutions to improve the lives of patients with complex heart conditions [5]. - The company emphasizes understanding unmet patient needs and enhancing the patient experience through new treatment approaches that allow for self-management [5]. Group 2: Product Details - Etripamil is a novel calcium channel blocker nasal spray designed for self-administration, targeting symptomatic episodes of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR) [4]. - The product is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025 [2]. - Etripamil aims to provide healthcare providers with a new treatment option for on-demand care and patient self-management, potentially enhancing patients' control over their condition [4]. Group 3: Upcoming Event - Milestone Pharmaceuticals will host an investor event on February 25, 2025, in New York, featuring presentations from the CEO and Chief Commercial Officer, detailing the commercial strategy for etripamil [1][2]. - A live question and answer session will follow the formal presentation, allowing for direct engagement with investors [3].

- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targeted for mid-2025 - Plans to initiate Phase 3 Study in AFib-RVR in H1 2025 MONTREAL and CHARLOTTE, N.C., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today ...

Milestone Pharmaceuticals Inc. (MIST) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MIST's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves the 50-da ...

Exhibit 99.1 Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. "Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etrip ...

MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc.  (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “We believe that CARDAMYST has the potential to improve how ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares MIST The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...

MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled trial in China evaluating the efficacy and safety of etripamil nasal spray in paroxysmal supraventricular tachycar ...

MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, ...